DK2972359T3 - Berigelse af cirkulerende tumorceller ved udtømning af hvide blodceller - Google Patents
Berigelse af cirkulerende tumorceller ved udtømning af hvide blodceller Download PDFInfo
- Publication number
- DK2972359T3 DK2972359T3 DK14721102.3T DK14721102T DK2972359T3 DK 2972359 T3 DK2972359 T3 DK 2972359T3 DK 14721102 T DK14721102 T DK 14721102T DK 2972359 T3 DK2972359 T3 DK 2972359T3
- Authority
- DK
- Denmark
- Prior art keywords
- enrichment
- exhausting
- white blood
- circulating tumor
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787611P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027701 WO2014152758A1 (en) | 2013-03-15 | 2014-03-14 | Enrichment of circulating tumor cells by depleting white blood cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2972359T3 true DK2972359T3 (da) | 2020-11-09 |
Family
ID=50631046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14721102.3T DK2972359T3 (da) | 2013-03-15 | 2014-03-14 | Berigelse af cirkulerende tumorceller ved udtømning af hvide blodceller |
Country Status (20)
Country | Link |
---|---|
US (2) | US9823238B2 (da) |
EP (1) | EP2972359B1 (da) |
JP (1) | JP6563379B2 (da) |
CN (1) | CN105026934A (da) |
AU (1) | AU2014239168A1 (da) |
BR (1) | BR112015022962A2 (da) |
CA (1) | CA2906900A1 (da) |
CY (1) | CY1123698T1 (da) |
DK (1) | DK2972359T3 (da) |
ES (1) | ES2846224T3 (da) |
HK (2) | HK1216442A1 (da) |
HR (1) | HRP20201907T1 (da) |
HU (1) | HUE052519T2 (da) |
LT (1) | LT2972359T (da) |
MX (1) | MX365713B (da) |
PL (1) | PL2972359T3 (da) |
PT (1) | PT2972359T (da) |
RS (1) | RS61052B1 (da) |
SI (1) | SI2972359T1 (da) |
WO (1) | WO2014152758A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108061804B (zh) * | 2016-11-09 | 2020-05-12 | 北京大学人民医院 | 用于诊断子宫内膜异位症的生物标志物 |
CN109991410B (zh) * | 2017-12-29 | 2022-07-05 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
JP7494460B2 (ja) * | 2018-11-02 | 2024-06-04 | 東ソー株式会社 | 細胞に結合可能な担体の製造方法 |
CN109439732B (zh) * | 2018-12-25 | 2024-04-12 | 迈迪速能医学技术(天津)有限公司 | 一种用于三维无创肿瘤早筛的试剂盒 |
US11890616B2 (en) | 2019-03-26 | 2024-02-06 | The Curators Of The University Of Missouri | Microfluidic device for capture of micrometer scale objects and methods of using the device |
KR102346111B1 (ko) * | 2020-02-07 | 2022-01-03 | 주식회사 싸이토딕스 | Ctc 분리용 마그네틱 비드 및 이를 이용한 ctc 분리방법 |
AU2021336112A1 (en) * | 2020-09-02 | 2023-05-04 | Menarini Silicon Biosystems S.P.A. | System, kit, method and process for handling a sample |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU658132B2 (en) | 1989-11-13 | 1995-04-06 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
WO1999041613A1 (en) | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
US6342344B1 (en) * | 1998-07-31 | 2002-01-29 | Stemcell Technologies Inc. | Antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions |
US7364921B1 (en) * | 1999-01-06 | 2008-04-29 | University Of Medicine And Dentistry Of New Jersey | Method and apparatus for separating biological materials and other substances |
CA2381732A1 (en) * | 1999-08-21 | 2001-03-01 | John S. Fox | High sensitivity biomolecule detection with magnetic particles |
CN1871517A (zh) | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
CA2504279A1 (en) * | 2005-04-15 | 2006-10-15 | University Of Saskatchewan | Materials and method of modulating the immune response using t helper-antigen presenting cells |
US7901950B2 (en) | 2005-08-12 | 2011-03-08 | Veridex, Llc | Method for assessing disease states by profile analysis of isolated circulating endothelial cells |
US8889361B2 (en) * | 2007-09-19 | 2014-11-18 | The Research Foundation For The State University Of New York | Gene expression signatures in enriched tumor cell samples |
KR101604649B1 (ko) | 2007-11-27 | 2016-03-18 | 베리덱스, 엘엘씨 | 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화 |
US20090191535A1 (en) * | 2007-12-22 | 2009-07-30 | Mark Carle Connelly | Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells |
CN101469310B (zh) | 2007-12-28 | 2014-03-19 | 北京百奥科生物技术有限公司 | 从生物学样品富集靶细胞的方法及除去白细胞的方法 |
US8569077B2 (en) | 2008-05-19 | 2013-10-29 | Veridex, Llc | Imaging of immunomagnetically enriched rare cells |
US9034658B2 (en) * | 2009-11-23 | 2015-05-19 | The General Hospital Corporation | Microfluidic devices for the capture of biological sample components |
US9624469B2 (en) * | 2010-07-22 | 2017-04-18 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
ES2799581T3 (es) | 2011-07-21 | 2020-12-18 | Menarini Silicon Biosystems Spa | Ensayo para capturar y detectar células de mieloma múltiple circulantes de la sangre |
AU2013235600B2 (en) * | 2012-03-21 | 2017-12-07 | Dana-Farber Cancer Institute, Inc. | Isolation and use of human lymphoid organ-derived suppressive stromal cells |
US20140011685A1 (en) | 2012-07-03 | 2014-01-09 | Yixin Wang | Genomic diagnostics using circulating endothelial cells |
-
2014
- 2014-03-14 HU HUE14721102A patent/HUE052519T2/hu unknown
- 2014-03-14 LT LTEP14721102.3T patent/LT2972359T/lt unknown
- 2014-03-14 US US14/211,630 patent/US9823238B2/en active Active
- 2014-03-14 BR BR112015022962A patent/BR112015022962A2/pt not_active IP Right Cessation
- 2014-03-14 PL PL14721102T patent/PL2972359T3/pl unknown
- 2014-03-14 RS RS20201358A patent/RS61052B1/sr unknown
- 2014-03-14 AU AU2014239168A patent/AU2014239168A1/en not_active Abandoned
- 2014-03-14 MX MX2015012341A patent/MX365713B/es active IP Right Grant
- 2014-03-14 DK DK14721102.3T patent/DK2972359T3/da active
- 2014-03-14 CN CN201480015641.2A patent/CN105026934A/zh active Pending
- 2014-03-14 PT PT147211023T patent/PT2972359T/pt unknown
- 2014-03-14 WO PCT/US2014/027701 patent/WO2014152758A1/en active Application Filing
- 2014-03-14 EP EP14721102.3A patent/EP2972359B1/en active Active
- 2014-03-14 JP JP2016502523A patent/JP6563379B2/ja active Active
- 2014-03-14 ES ES14721102T patent/ES2846224T3/es active Active
- 2014-03-14 CA CA2906900A patent/CA2906900A1/en not_active Abandoned
- 2014-03-14 SI SI201431716T patent/SI2972359T1/sl unknown
-
2016
- 2016-04-19 HK HK16104443.7A patent/HK1216442A1/zh unknown
- 2016-06-30 HK HK16107632.1A patent/HK1219776A1/zh unknown
-
2017
- 2017-10-11 US US15/729,957 patent/US10365266B2/en active Active
-
2020
- 2020-11-30 HR HRP20201907TT patent/HRP20201907T1/hr unknown
- 2020-12-02 CY CY20201101139T patent/CY1123698T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MX365713B (es) | 2019-06-11 |
US20140335542A1 (en) | 2014-11-13 |
US10365266B2 (en) | 2019-07-30 |
CY1123698T1 (el) | 2022-03-24 |
AU2014239168A1 (en) | 2015-10-29 |
SI2972359T1 (sl) | 2021-01-29 |
HK1216442A1 (zh) | 2016-11-11 |
MX2015012341A (es) | 2016-06-06 |
JP6563379B2 (ja) | 2019-08-21 |
HUE052519T2 (hu) | 2021-05-28 |
LT2972359T (lt) | 2020-12-10 |
US20180045712A1 (en) | 2018-02-15 |
ES2846224T3 (es) | 2021-07-28 |
WO2014152758A1 (en) | 2014-09-25 |
EP2972359B1 (en) | 2020-09-23 |
HRP20201907T1 (hr) | 2021-01-22 |
CN105026934A (zh) | 2015-11-04 |
RS61052B1 (sr) | 2020-12-31 |
EP2972359A1 (en) | 2016-01-20 |
US9823238B2 (en) | 2017-11-21 |
PT2972359T (pt) | 2020-10-29 |
JP2016519286A (ja) | 2016-06-30 |
CA2906900A1 (en) | 2014-09-25 |
PL2972359T3 (pl) | 2021-03-08 |
HK1219776A1 (zh) | 2017-04-13 |
BR112015022962A2 (pt) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
DK3071223T3 (da) | Cell | |
DK3213084T4 (da) | Fremgangsmåde til berigelse af cirkulerende tumor dna | |
DK3351645T3 (da) | Pyrofosforolytisk sekventering ved anvendelse af nanoporer | |
DK2972359T3 (da) | Berigelse af cirkulerende tumorceller ved udtømning af hvide blodceller | |
DK3351620T3 (da) | Metabolsk optimeret cellekultur | |
DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK2897611T3 (da) | Fremgangsmåder til behandling af hepatitis c | |
DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
DK2943561T3 (da) | Fotobioreaktor | |
DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
DK2931313T3 (da) | Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer | |
DK3058078T3 (da) | Manipulation af carbonhydridmetabolisme i gær | |
DK2968483T3 (da) | Subkutan indgivelse af adamts13 | |
DK3063264T3 (da) | Tørring af mikroorganismer | |
DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
DK3077523T3 (da) | Produktion af thapsigarginer ved hjælp af Thapsia cellesuspensionskultur | |
DK2822301T3 (da) | Bestemmelse af individuelle HRTF | |
DK3024816T3 (da) | Ppar-sparende forbindelser til behandling af metaboliske sygdomme | |
DK3060674T3 (da) | Forbedret fermenteringsproces ved hjælp af en transglycosidase | |
DK3078107T3 (da) | Forbedring af inverterregulering |